Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

NCT03289780 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study will also look to establish whether new investigational tests can help better predict the effectiveness of certain medications for certain patients. These new investigational tests are only for research purposes at this time.

Conditions Studied

Study Locations (20)

Georgia

  • South Eastern Regional Medical Center — Newnan
  • Summit Cancer Care — Savannah
  • South Georgia Medical Center — Valdosta

Alabama

  • Oncology Specialties, PC; Clearview Cancer Institute — Huntsville
  • Lewis & Faye Manderson Cancer Center at DCH Regional Medical Center — Tuscaloosa

Arkansas

  • Highlands Oncology Group — Fayetteville
  • St. Bernards Cancer Center Hematology / Oncology — Jonesboro

Florida

  • Boca Raton Regional Hospital -Lynn Cancer Institute — Boca Raton
  • Lake City Cancer Care, LLC — Lake City

Illinois

  • Edward-Elmhurst Healthcare — Naperville
  • Illinois Cancer Care — Peoria

Indiana

  • Franciscan St. Francis Health — Indianapolis
  • Franciscan Health Woodland Cancer Center — Michigan City

Louisiana

  • Ponchartrain Cancer Center — Covington
  • Christus Health — Shreveport

Missouri

  • Central Care Cancer Center — Bolivar
  • Phelps County Regional Medical Center — Rolla

Trial Details

FieldValue
Enrollment Target 5,006 participants
Start Date 2016-04-04
Est. Completion 2025-12

Sponsor

Biodesix

3 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03289780

The ClinicalTrials.gov registry entry for NCT03289780 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 5,006 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biodesix, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03289780 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Georgia, Alabama, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03289780 about?

NCT03289780 is a clinical study titled "Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects". The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to be...

What is the current status of trial NCT03289780?

This trial is currently active not recruiting. The enrollment target is 5,006 participants. The study started on 2016-04-04. Estimated completion is 2025-12.

What conditions does trial NCT03289780 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT03289780?

This trial is sponsored by Biodesix, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03289780 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial